Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Giant Biogene Holding Co. Ltd. ( (HK:2367) ) has shared an announcement.
Giant Biogene Holding Co., Ltd has announced a board meeting scheduled for August 27, 2025, to review and approve the interim results for the first half of the year and discuss the potential payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
More about Giant Biogene Holding Co. Ltd.
Giant Biogene Holding Co., Ltd is a company incorporated in the Cayman Islands, operating with limited liability. It is listed on the Stock Exchange of Hong Kong, focusing on the biogene industry.
Average Trading Volume: 13,894,641
Technical Sentiment Signal: Buy
Current Market Cap: HK$62.39B
For detailed information about 2367 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money